[{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx Announces Positive Results in Phase 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin for Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx Completes Dosing of Last Patient in Phase 2 Clinical Study of Mizagliflozin for the Treatment of Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Vogenx
KWA 0711 (mizagliflozin) is an investigational first-in-class, oral, SGLT1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of post-bariatric hypoglycemia.
KWA-0711 (mizagliflozin) is a novel first in class SGLT1 inhibitor, small molecule therapeutic candidate. It is being evaluated for the treatment of post-bariatric hypoglycemia.
Mizagliflozin Encapsulated or Liquid Formulation is a novel first in class small molecule therapeutic candidate being developed for Post-Bariatric Hypoglycemia.